Last reviewed · How we verify
Cocaine 4%
At a glance
| Generic name | Cocaine 4% |
|---|---|
| Also known as | Cocaine hydrochloride 4% |
| Sponsor | Rigshospitalet, Denmark |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- (Effect of Toy Nebulizer Versus Distraction Cards on Children's Fear and Parental Satisfaction During Nebulization Therapy: A Comparative Study (NA)
- Harm Reduction Services (NA)
- Repurposing Semaglutide for the Treatment of Cocaine Use Disorder (PHASE2)
- Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder (PHASE2)
- Phase1, STP7 Cocaine Drug-Drug Interaction Study (PHASE1)
- The APS Phenotyping Study
- Scapulothoracic Joint Mobilization With or Without Acromioclavicular Joint Mobilization in Sub-acromial Pain Syndrome (NA)
- Reward-based Technology to Improve OUD Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cocaine 4% CI brief — competitive landscape report
- Cocaine 4% updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI